Q32 Bio (QTTB) Common Equity (2017 - 2026)

Q32 Bio has reported Common Equity for 10 years, with the latest figure at $46.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 1253.79% year-over-year to $46.3 million; the trailing twelve-month figure through Mar 2026 stood at $46.3 million (up 1253.79% YoY), and the FY2025 full-year result was $42.0 million, up 640.33% from the prior year.
• Common Equity for Q1 2026 stood at $46.3 million, up from $42.0 million in the prior quarter.
• The five-year high for Common Equity was $266.3 million in Q1 2022, with the low at -$182.9 million in Q4 2023.
• Average Common Equity over 5 years is $7.4 million, with a median of $5.7 million recorded in 2024.
• Year-over-year, Common Equity sank 200.84% in 2025 and jumped 1253.79% in 2026.
• Tracing QTTB's Common Equity over 5 years: stood at -$130.7 million in 2022, then tumbled by 39.94% to -$182.9 million in 2023, then soared by 103.1% to $5.7 million in 2024, then jumped by 640.33% to $42.0 million in 2025, then climbed by 10.23% to $46.3 million in 2026.
• The last three Common Equity figures came in at $46.3 million (Q1 2026), $42.0 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.

Peer Comparison